Correction to Lancet Diabetes Endocrinol 2018; 6: 370-81

No authors listed

Published Erratum

No authors listed. Lancet Diabetes Endocrinol. 2018 Jun.

. 2018 Jun;6(6):e5.

doi: 10.1016/S2213-8587(18)30152-9.

No abstract available

Erratum for

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z. Ludvik B, et al. Lancet Diabetes Endocrinol. 2018 May;6(5):370-381. doi: 10.1016/S2213-8587(18)30023-8. Epub 2018 Feb 23. Lancet Diabetes Endocrinol. 2018. PMID: 29483060 Clinical Trial.